Floatz Rating
BB71/100
Confidence
Indicative
Sponsor
China National Center for Cardiovascular Diseases
Modality
Small molecule
Development Phase
Phase 4 / Approved
Status
Active
Evidence ledger · v0.2
Clinical Evidence
Clinical track record: trial progression, reported outcomes, safety signals, and endpoint quality.
75High confidence
Detailed axis rationale is planned and will be published soon.
| Trial | Phase | Status | N | Primary endpoint | Readout |
|---|---|---|---|---|---|
NCT07471139CT.gov SWITCH: Apixaban vs Vitamin K in HM3 | — | Not Yet Recruiting | — | — | — |
NCT05540587CT.gov Efficacy and Safety of Edoxaban in Patients With Atrial Fibrillation and Mitral Stenosis | — | Unknown | — | — | — |
NCT03684564CT.gov RIvaroxaban for Stroke Patients With AntiPhospholipid Syndrome | — | Completed | — | — | — |
NCT04878497CT.gov Prospective Monitoring of Non-Vitamin K Oral Anticoagulants in Older Adults With Atrial Fibrillation and Frailty | — | Unknown | — | — | — |
NCT03702582CT.gov Rivaroxaban vs. Warfarin for Post Cardiac Surgery Atrial Fibrillation | — | Completed | — | — | — |
NCT03566303CT.gov Rivaroxaban vs Warfarin in Patients With Metallic Prosthesis | — | Terminated | — | — | — |
NCT02889562CT.gov Apixaban Versus Warfarin for the Management of Post-operative Atrial Fibrillation | — | Completed | — | — | — |
NCT02283294CT.gov Apixaban for Early Prevention of Recurrent Embolic Stroke and Hemorrhagic Transformation | — | Completed | — | — | — |
NCT01747746CT.gov Anticoagulation With Rivaroxaban in Cardioversion -The ARC Study | — | Completed | — | — | — |
NCT01518231CT.gov Autologous Hematopoietic Stem Cell Transplantation in Ischemic Stroke | — | Unknown | — | — | — |
Show 7 more trialsShow fewer
NCT02065388CT.gov Pharmacogenetic Dosing of Warfarin | — | Completed | — | — | — |
NCT00781391CT.gov Global Study to Assess the Safety and Effectiveness of Edoxaban (DU-176b) vs Standard Practice of Dosing With Warfarin in Patients With Atrial Fibrillation | — | Completed | — | — | — |
NCT00806624CT.gov DU-176b Phase 2 Dose Finding Study in Subjects With Non-valvular Atrial Fibrillation | — | Completed | — | — | — |
NCT00403767CT.gov An Efficacy and Safety Study of Rivaroxaban With Warfarin for the Prevention of Stroke and Non-Central Nervous System Systemic Embolism in Patients With Non-Valvular Atrial Fibrillation | — | Completed | — | — | — |
NCT00262600CT.gov Randomized Evaluation of Long Term Anticoagulant Therapy (RE-LY) With Dabigatran Etexilate | — | Completed | — | — | — |
NCT00238667CT.gov To Determine the Feasibility of a Clinical Trial Comparing Anticoagulants Versus Antiplatelets in the Acute Treatment of Patients With Cervical Artery Dissection | — | Completed | — | — | — |
NCT00027066CT.gov Warfarin Versus Aspirin Recurrent Stroke Study | — | Completed | — | — | — |
Competitive Position
Competitive setting: how crowded the indication is, class-level failures, and timing against rivals.
65High confidence
Detailed axis rationale is planned and will be published soon.
Same indication · Stroke Disorder
| Asset | Sponsor | Phase | Rating |
|---|---|---|---|
| Warfarin (this asset) | China National Center for Cardiovascular Diseases | Approved | BB · 71 |
| Aggrenox | Boehringer Ingelheim | P4 | BBB |
| Incobotulinumtoxina | Parc de Salut Mar | P4 | BBB |
| Atenolol | Northern California Institute of Research and Education | P4 | BBB |
| Dextromethorphan | University of Florida | P4 | BBB |
| Tenecteplase | Assistance Publique - Hôpitaux de Paris | P4 | BBB |
| Rivaroxaban | China National Center for Cardiovascular Diseases | P4 | BBB |
| Nerinetide | NoNO Inc. | P3 | BBB |
| Clopidogrel | Shanghai CureGene Pharmaceutical Co., Ltd. | P4 | BB |
+42 more in the Stroke Disorder cohort
Other indications for Warfarin
| Indication | Sponsor | Phase | Rating |
|---|---|---|---|
| Venous Thromboembolism | — | P4 | A · 81 |
| Atrial Fibrillation | — | P4 | BBB · 77 |
| Hemorrhagic Disease | — | P4 | BBB · 74 |
Scientific Foundation
Strength of the underlying biology: target validation, tractability, modality fit, and how related mechanisms have fared.
NR
Planned for methodology v0.2.
Development Feasibility
How realistically the program can be executed, drawing on modality precedent, enrollment dynamics, and sponsor delivery.
NR
Planned for methodology v0.2.
Commercial Opportunity
Commercial prize: addressable population, unmet need, and the value case for the indication.
NR
Planned for methodology v0.2.
IP & Exclusivity
Exclusivity position, covering patent protection and freedom-to-operate runway.
NR
Planned for methodology v0.2.
Manufacturing & Supply
Manufacturing and supply readiness, driven by modality process and scale-up risk.
NR
Planned for methodology v0.2.
Related assets
Citation
Floatz Terminal. Warfarin in Stroke Disorder. Methodology v0.2. Rated under v0.2 effective July 8, 2026. Last refreshed July 8, 2026. Accessed July 14, 2026. https://terminal.floatz.ai/assets/warfarin-stroke-disorder
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →